Oncology Today with Dr Neil Love cover image

HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

Oncology Today with Dr Neil Love

00:00

Selecting second-line after FLOT and immunotherapy

Panel recommends anti‑HER2 therapy inclusion, considers T-DXd or FOLFIRI+trastuzumab, and notes timing after FLOT.

Play episode from 18:20
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app